Evidence map›Paper›PMID 25679813›Full record

ArticlePLoS genetics2015

Discovery of transcription factors and regulatory regions driving in vivo tumor development by ATAC-seq and FAIRE-seq open chromatin profiling.

Kristofer Davie, Jelle Jacobs, Mardelle Atkins, Delphine Potier, Valerie Christiaens, Georg Halder, Stein Aerts

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 185 citations in OpenAlex.

  1. Article
  2. Article
  3. aBIOTECH · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Cis-Regulatory Elements in Mammals.International journal of molecular sciences · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kristofer DavieLaboratory of Computational Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium.
Jelle JacobsLaboratory of Computational Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium.
Mardelle AtkinsLaboratory of Growth Control and Cancer Research, Center for Human Genetics, KU Leuven, Leuven, Belgium; VIB Center for the Biology of Disease, Laboratory for Molecular Cancer Biology, Leuven, Belgium.
Delphine PotierLaboratory of Computational Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium.
Valerie ChristiaensLaboratory of Computational Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium.
Georg HalderLaboratory of Growth Control and Cancer Research, Center for Human Genetics, KU Leuven, Leuven, Belgium; VIB Center for the Biology of Disease, Laboratory for Molecular Cancer Biology, Leuven, Belgium.
Stein AertsLaboratory of Computational Biology, Center for Human Genetics, KU Leuven, Leuven, Belgium.
KU Leuven · BEVIB-KU Leuven Center for Cancer Biology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genomic enhancers regulate spatio-temporal gene expression by recruiting specific combinations of transcription factors (TFs). When TFs are bound to active regulatory regions, they displace canonical nucleosomes, making these regions biochemically detectable as nucleosome-depleted regions or accessible/open chromatin. Here we ask whether open chromatin profiling can be used to identify the entire repertoire of active promoters and enhancers underlying tissue-specific gene expression during normal development and oncogenesis in vivo. To this end, we first compare two different approaches to detect open chromatin in vivo using the Drosophila eye primordium as a model system: FAIRE-seq, based on physical separation of open versus closed chromatin; and ATAC-seq, based on preferential integration of a transposon into open chromatin. We find that both methods reproducibly capture the tissue-specific chromatin activity of regulatory regions, including promoters, enhancers, and insulators. Using both techniques, we screened for regulatory regions that become ectopically active during Ras-dependent oncogenesis, and identified 3778 regions that become (over-)activated during tumor development. Next, we applied motif discovery to search for candidate transcription factors that could bind these regions and identified AP-1 and Stat92E as key regulators. We validated the importance of Stat92E in the development of the tumors by introducing a loss of function Stat92E mutant, which was sufficient to rescue the tumor phenotype. Additionally we tested if the predicted Stat92E responsive regulatory regions are genuine, using ectopic induction of JAK/STAT signaling in developing eye discs, and observed that similar chromatin changes indeed occurred. Finally, we determine that these are functionally significant regulatory changes, as nearby target genes are up- or down-regulated. In conclusion, we show that FAIRE-seq and ATAC-seq based open chromatin profiling, combined with motif discovery, is a straightforward approach to identify functional genomic regulatory regions, master regulators, and gene regulatory networks controlling complex in vivo processes.

Indexed as

AnimalsCarcinogenesisChromatinDrosophilaDrosophila ProteinsEnhancer Elements, GeneticEyeGene Regulatory NetworksHumansInsulator ElementsPromoter Regions, GeneticSTAT Transcription FactorsTranscription Factor AP-1ChromatinDrosophila ProteinsStat92E protein, DrosophilaSTAT Transcription FactorsTranscription Factor AP-1

Identifiers

PMID25679813
PMCPMC4334524
OpenAlexW2029947491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.